JPRN-UMIN000036448已完成未知
A confirmation study of the influence for blood vessel by consumption of test food - A confirmation study of the influence for blood vessel by consumption of test food
CPCC Company Limited0 个研究点目标入组 24 人开始时间: 2020年4月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1)Subjects who are given continuous treatment by taking medicines. 2)Subjects who have previous and/or current medical history of serious disease (e.g.,digestive organ,circulatory organ,respiratory organ and urinary organ etc.). 3)Subjects who excessive alcohol intake. 4)Subjects who have extremely irregular dining habits,and subjects who have midnight work or irregular shift work. 5)Subjects who have previous medical history of drug and/or food allergy. 6)Subjects who regularly having medicines, quasi-drugs,food for specified health uses,foods with function claim,health food and/or supplements. 7)Subjects who participated within one month prior to the current study and/or who plan to participate the other clinical tests. 8)Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. 9)Subjects who donated over 400mL blood and/or blood components within the last three month to the current study. 10)Subjects who will be collected over 1200mL blood and/or blood components,when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. 11)Others who have been determined ineligible by principal investigator or sub-investigator.
研究者
相似试验
已完成
不适用
A study examining the relationship between blood flow waveform indices and lifestyle-related disease indicesHealthy adultsJPRN-UMIN000045013Kao Corporation200
招募中
不适用
Clinical study to evaluate the efficacy of blood purification therapy on cholesterol crystal embolismcholesterol crystal embolismJPRN-UMIN000009306Incorporated administrative agency, Japan Community Health care Organization, Sendai Hospital35
进行中（未招募）
不适用
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2010-018863-40-DEBayer HealthCare AG18
进行中（未招募）
不适用
An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatment in subjects with symptomatic pulmonary arterial hypertension - PATENT PLUSPulmonary arterial hypertension.MedDRA version: 9.1Level: LLTClassification code 10064911EUCTR2010-018863-40-ITBayer Health Care AG36
进行中（未招募）
不适用
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018863-40-CZBayer HealthCare AG36